Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice

Lei Hao, Sheyenne Scott, Mehrnaz Abbasi, Yujiao Zu, Md Shahjalal Hossain Khan, Yang Yang, Dayong Wu, Ling Zhao, and Shu Wang

Department of Nutritional Sciences, Texas Tech University, Lubbock, Texas (L.H., S.S., M.A., Y.Z., M.S.H.K., S.W.); Department of Nutrition, University of Tennessee, Knoxville, Tennessee (Y.Y., L.Z.); and Nutrition Immunology Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts (D.W.)

Received December 11, 2018; accepted March 22, 2019

ABSTRACT

Mirabegron, a β3-adrenergic receptor agonist, has been shown to stimulate the activity of brown fat and increase the resting metabolic rate in humans. However, it is unknown whether mirabegron can reduce body weight and improve metabolic health. We investigated the antiobesity effects of mirabegron using both in vitro and in vivo models. Mouse brown preadipocytes and 3T3-L1 cells were treated with different concentrations of mirabegron (0.03–3 µg/ml), and the expression of brown fat-related genes was measured by quantitative real-time polymerase chain reaction. Furthermore, male C57BL/6J mice were fed a high-fat diet for 10 weeks, and mirabegron (2 mg/kg body weight) or a vehicle control was delivered to the interscapular brown adipose tissue (iBAT) using ALZET osmotic pumps from week 7 to 10. The metabolic parameters and tissues were analyzed. In both mouse brown preadipocytes and 3T3-L1 cells, mirabegron stimulated uncoupling protein 1 (UCP1) expression. In animal studies, mirabegron-treated mice had a lower body weight and adiposity. Lipid droplets in the iBAT of mirabegron-treated mice were fewer and smaller in size compared with those from vehicle-treated mice. H&E staining and immunohistochemistry indicated that mirabegron increased the abundance of beige cells in inguinal white adipose tissue (iWAT). Compared with vehicle-treated mice, mirabegron-treated mice had a higher gene expression of UCP1 (14-fold) and cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) (4-fold) in iWAT. Furthermore, mirabegron-treated mice had improved glucose tolerance and insulin sensitivity. Taken together, mirabegron enhances UCP1 expression and promotes browning of iWAT, which are accompanied by improved glucose tolerance and insulin sensitivity and prevention from high-fat diet-induced obesity.

Introduction

Obesity affects 35.0% of adult men and 40.4% of adult women in the United States (Flegal et al., 2016). Obesity increases the risk of several chronic diseases such as type 2 diabetes, heart disease and even some types of cancers. In addition, obesity creates a huge health care costs burden. A meta-analysis shows that the United States spent $149.4 billion annually on obesity-related health care between 2008 and 2012 (Kim and Basu, 2016), and the number is expected to rise over the next few decades (Cawley and Meyerhoefer, 2012).

Two kinds of adipose tissue exist in mammals, with distinct physiologic functions: white adipose tissue (WAT), which is metabolizing glucose, fatty acids, and other chemicals to produce heat (Cannon and Nedergaard, 2004; Ozaki et al., 2011; Kazak et al., 2015). The brown-like adipocytes found in WAT are called brite/beige adipocytes. Similar to classic brown adipocytes in BAT, beige adipocytes possess multilocular lipid droplets, a large number of mitochondria, and unique brown fat gene expression markers such as uncoupling protein 1 (UCP1), cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA), and peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α (PGC1α) (Harms and Seale, 2013).

Traditionally, it was thought that BAT only existed in rodents and human infants. In 2009, several studies using positron emission tomography scanning showed that human adults do have active BAT (Cypess et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen et al., 2009). The fact that activation of BAT can increase energy expenditure makes BAT a promising new target for obesity and type 2 diabetes treatment.

This work was supported by the College of Human Sciences of Texas Tech University and the National Institutes of Health National Center for Complementary & Integrative Health (Grant R15AT008733).

https://doi.org/10.1124/jpet.118.255778.

ABBREVIATIONS: β3-AR, β3 adrenergic receptor; BAT, brown adipose tissue; BRL37344, sodium:2-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][amino]propyl]phenoxy]acetate; CHD, chow diet; CIDEA, cell death-inducing DNA fragmentation factor alpha-like effector A; CL316243, disodium; S-[(2R)-2-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl][amino]propyl]-1, 3-benzodioxole-2,2-dicarboxylate; CPT1, carnitine palmitoyltransferase 1; DEX, dexamethasone; HFD, high-fat diet; HSL, hormone-sensitive lipase; iBAT, interscapular brown adipose tissue; iWAT, inguinal white adipose tissue; MA, mirabegron; PCR, polymerase chain reaction; PGC-1α, PPAR-γ coactivator 1α; PPARγ, peroxisome proliferator-activated receptor γ; PRDM16, PR domain containing 16; P/S, penicillin/streptomycin; TMEM26, transmembrane protein 26; UCP1, uncoupling protein 1; VEGFa, vascular endothelial growth factor a; VEH, vehicle; WAT, white adipose tissue.
Most medications approved by U.S. Food and Drug Administration for the treatment of obesity reduce energy intake by either suppressing appetite or reducing fat absorption in the intestine (Arch, 2015; Omran, 2017). However, none of the antiobesity drugs targets energy expenditure through stimulating BAT activity. Several strategies, such as genetic manipulations, pharmaceutical agents, dietary factors, and cold challenge, have been used to promote BAT activity or the browning of WAT (Merlin et al., 2016). One area of focus has been the promotion of energy expenditure through activation of β3-adrenergic receptor (β3-AR) on brown adipocytes (Arch, 2011).

Human β3-AR was identified in 1989 (Emorine et al., 1989), and it was shown to be expressed in many tissues, including WAT, BAT, urinary bladder, heart, and other tissues (Ursin et al., 2009). The adrenergic signaling regulates the activity of enzymes involved in lipolysis and fuel utilization in BAT (Townsend and Tseng, 2014). A number of animal studies have shown that β3-AR agonists have antiobesity and/or antidiabetic effects (Umekawa et al., 1997; Kiso et al., 1999; Williams et al., 1999; Arch, 2002). However, most of these β3-AR agonists such as disodium-5-[(2R)-2-[[2(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL316243), ritobegron, solabegron, and sodium-2-[(2R)-2-[[2(R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxacetate (BRL37344), have not been approved for the treatment of obesity and its related metabolic disorders due to their low efficacy and high toxicity in humans (Arch, 2011).

Mirabegron is a β3-AR agonist that was approved for treating overactive bladder in the United States in 2012 (Sacco et al., 2014). Several randomized, double-blind, and placebo-controlled studies have shown that the adverse events were comparable between mirabegron-treated and placebo groups (Yamaguchi et al., 2015; Herschorn et al., 2017; Tubaro et al., 2018). Mirabegron was shown to be well tolerated and to have higher patient compliance due to its fewer side effects compared with the anticholinergic drugs (Dehvari et al., 2018). More interestingly, one recent study showed that mirabegron (200 mg) acutely stimulated the activity of BAT thermogenesis and raised the resting metabolic rate in healthy individuals (Cypess et al., 2015). However, this dose is much higher than the recommended daily dose (50 mg) for treating overactive bladder (Cypess et al., 2015). An animal study demonstrated that acute mirabegron administration (0.125 mM indomethacin, 2 mg/ml dexamethasone (DEX), and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX). After 48 hours, the cells were incubated in differentiation medium containing DMEM supplemented with 20% FBS, 20 nM insulin, and 1 nM triiodothyronine for 6 days. The differentiation medium was changed every 48 hours.

This cell line expresses β3-AR after differentiation (our pilot study). To study the effects of mirabegron on brown preadipocytes, mirabegron (0.03, 0.3, and 3 μg/ml) (Santa Cruz Biotechnology, Inc., Dallas, TX), or the vehicle control dimethyl sulfoxide (DMSO), or the positive control CL316243 (0.3 μg/ml), a selective β3-AR agonist (Klein et al., 1999), was added to the differentiation medium and replaced with each change of the differentiation medium during the differentiation process (6 days).

### Materials and Methods

#### Culturing of Murine Brown Preadipocytes and Treatments.

The murine brown preadipocyte line was provided by Dr. Johannes Klein, who developed the cell line from the fibrostriatal fraction of iBAT of newborn C57BL/6J mice (Klein et al., 2002). The method to culture brown preadipocytes was previously described elsewhere (Hao et al., 2018). Briefly, mouse brown preadipocytes were maintained in regular growth medium containing DMEM with 20% FBS at 37°C in a humidified incubator with 5% CO₂, until they reached confluence. To induce differentiation, the cells were initially incubated in induction medium containing DMEM supplemented with 20% FBS, 20 nM insulin, 1 nM triiodothyronine, 0.125 mM indomethacin, 2 μg/ml dexamethasone (DEX), and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX). After 48 hours, the cells were incubated in differentiation medium containing DMEM supplemented with 20% FBS, 20 nM insulin, and 1 nM triiodothyronine for 6 days. The differentiation medium was changed every 48 hours.

This cell line expresses β3-AR after differentiation (our pilot study). To study the effects of mirabegron on brown preadipocytes, mirabegron (0.03, 0.3, and 3 μg/ml) (Santa Cruz Biotechnology, Inc., Dallas, TX), or the vehicle control dimethyl sulfoxide (DMSO), or the positive control CL316243 (0.3 μg/ml), a selective β3-AR agonist (Klein et al., 1999), was added to the differentiation medium and replaced with each change of the differentiation medium during the differentiation process (6 days).

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Primer Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>36B4</td>
<td>Forward GCTCTGTGGTTCACACAGGGGAAG</td>
</tr>
<tr>
<td>UCPI</td>
<td>Reverse GCTCTGACAGGATGTCTGAGCC</td>
</tr>
<tr>
<td>DDR2</td>
<td>Reverse GCAGGAGGACCGAAGAGATAG</td>
</tr>
<tr>
<td>PPARγ</td>
<td>Reverse ATTCGCCCAACCCTTCTCCT</td>
</tr>
<tr>
<td>PGC1α</td>
<td>Reverse CATCCTTGGTACCTTGGTG</td>
</tr>
<tr>
<td>PRDM16</td>
<td>Reverse TCCAGAGTTTTGGACCTTGGTC</td>
</tr>
<tr>
<td>CIDEA</td>
<td>Reverse ATACCTGCCCCAGTTTGGCA</td>
</tr>
<tr>
<td>PRDM16</td>
<td>Reverse GCAGCTTGGTACCTTGGTG</td>
</tr>
<tr>
<td>RNF-1</td>
<td>Reverse GGCAACAGTAGCCACATTGGCT</td>
</tr>
<tr>
<td>ATGL</td>
<td>Reverse GCAGCTTGGTACCTTGGTG</td>
</tr>
<tr>
<td>HSL</td>
<td>Reverse ATACCTGCCCCAGCTTGGCA</td>
</tr>
<tr>
<td>CPT1</td>
<td>Reverse GAGCTCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>MCAD</td>
<td>Reverse CTACGTCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>COXII</td>
<td>Reverse GAGCTCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>INS</td>
<td>Reverse GCTACCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>ELOVL3</td>
<td>Reverse ACAGGGACGACACAAAAAC</td>
</tr>
<tr>
<td>Leptin</td>
<td>Reverse GTAAGGAGGACGAGGTTCC</td>
</tr>
<tr>
<td>CD137</td>
<td>Reverse CTGGCGACTTTCGGGAGG</td>
</tr>
<tr>
<td>TMEM26</td>
<td>Reverse ATCTGGTGGATACCTTGGAAG</td>
</tr>
</tbody>
</table>

**TABLE 1**

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Primer Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>COXII</td>
<td>Reverse GAGCTCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>INS</td>
<td>Reverse GCTACCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>ELOVL3</td>
<td>Reverse ACAGGGACGACACAAAAAC</td>
</tr>
<tr>
<td>Leptin</td>
<td>Reverse GTAAGGAGGACGAGGTTCC</td>
</tr>
<tr>
<td>CD137</td>
<td>Reverse CTGGCGACTTTCGGGAGG</td>
</tr>
<tr>
<td>TMEM26</td>
<td>Reverse ATCTGGTGGATACCTTGGAAG</td>
</tr>
</tbody>
</table>

**TABLE 2**

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Primer Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>COXII</td>
<td>Reverse GAGCTCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>INS</td>
<td>Reverse GCTACCTGCGCTGGCATCT</td>
</tr>
<tr>
<td>ELOVL3</td>
<td>Reverse ACAGGGACGACACAAAAAC</td>
</tr>
<tr>
<td>Leptin</td>
<td>Reverse GTAAGGAGGACGAGGTTCC</td>
</tr>
<tr>
<td>CD137</td>
<td>Reverse CTGGCGACTTTCGGGAGG</td>
</tr>
<tr>
<td>TMEM26</td>
<td>Reverse ATCTGGTGGATACCTTGGAAG</td>
</tr>
</tbody>
</table>

**AtGTL, adipose triglyceride lipase; COXII, cytochrome c oxidase subunit 2; CPT1, carnitine palmitoyltransferase 1; DI2O, type II iodothyronine deiodinase; DI2O, type II iodothyronine deiodinase; ELOVL3, elongation of very long chain fatty acids protein 3; HSL, hormone-sensitive lipase; LPL, lipoprotein lipase; MCAD, medium-chain acyl-CoA dehydrogenase; NRF-1, nuclear respiratory factor 1; PGC-1α, PPAR-γ coactivator 1α; PPARγ; peroxisome proliferator-activated receptor γ; PRDM16, PR domain containing 16; TMEM26, transmembrane protein 26; UCPI, uncoupling protein 1.**

---

Downloaded from jpet.aspetjournals.org at ASPET Journals on November 26, 2021
Culturing of Mouse 3T3-L1 Adipocytes and Treatments. Mouse 3T3-L1 preadipocytes purchased from the American Type Culture Collection (ATCC, Manassas, VA) were grown in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (P/S). To induce differentiation, the cells were cultured in DMEM containing 10% FBS, 1% P/S, IBMX (0.5 mM), DEX (1 μM), and insulin (10 μg/ml) for 3 days. The cells then were incubated in DMEM with 10% FBS, 1% P/S, and insulin (10 μg/ml) for 2 days. Subsequently, the cells were maintained in DMEM supplemented with 10% FBS and 1% P/S for an additional 2 days.

During the last day of differentiation, cells were treated with DMSO (vehicle control), mirabegron (3 μg/ml), or the positive control isoproterenol (ISO) (1 μM), a β3-AR agonist (Asano et al., 2014), for 6 hours before the cells were harvested for total RNA isolation. In addition, a subset of cells were only maintained in basal medium containing DMEM with 10% FBS and 1% P/S as a negative differentiation control.

Animals. Male C57BL/6J mice (6 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed in rooms with the temperature set at 22°C and a 12-hour light/dark cycle. The mice were initially group-housed (five/cage) and had ad libitum access to food and water. After 1 week of acclimation, the mice were fed a high-fat diet (HFD) (D12492; Research Diets, New Brunswick, NJ) for 6 weeks. The mice (13 weeks old) were randomized and divided into the following two groups (six mice per group): a mirabegron (MA) group (HFD + MA) and a vehicle control group that received DMSO (50%, vol%) and polyethylene glycol (50%, vol%) (HFD + VEH). Mirabegron (10 mg/ml) dissolved in DMSO (50%, vol%) and polyethylene glycol (50%, vol%) was put into ALZET osmotic pumps (model 2004; Durect Corporation, Cupertino, CA), which infused 0.25 μl/h of mirabegron, approximating 2 mg/kg per day. The dosage of mirabegron was based on our pilot study and the literature on CL316243 in rodent studies (Xiao et al., 2015; Warner et al., 2016). The pumps were implanted subcutaneously on the back as previously described elsewhere (Hao et al., 2018). The mice were individually housed after the implantation.

Control C57BL/6J mice were fed chow diet (CHD) (2020X; Envigo, Indianapolis, IN) during the whole experiment. The food intake and body weight of all the mice were measured every week. Four weeks after implantation, the mice were fasted for 6 hours then euthanized by CO2 asphyxiation. Blood was drawn from the liver portal vein and kept in EDTA-coated tubes. Plasma was separated from the blood by centrifugation at 2000g for 20 minutes at 4°C. The organs and tissues were rapidly dissected, weighed, flash-frozen in liquid nitrogen, and stored at −80°C until analysis. A portion of iBAT and WAT was fixed with 10% phosphate-buffered formalin for histologic and immunohistochemistry analysis. The Institutional Animal Care & Use Committee of Texas Tech University approved all animal procedures (protocol number: 16028).

Plasma Lipid Profile. Plasma concentrations of high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, very-low-density lipoprotein-cholesterol, triglycerides, and total cholesterol were measured as previously described elsewhere (Hao et al., 2018).

H&E Staining. Portions of iBAT and inguinal white adipose tissue (iWAT) were fixed with 10% phosphate-buffered formalin and embedded in paraffin. The H&E staining was performed by the Department of Pathology of the Texas Tech University Health Sciences Center as previously described elsewhere (Hao et al., 2018). The images were taken under an Evos microscope (AMG, Bothell, WA). The neutral lipid occupied surface area of iBAT was quantified with ImageJ software (U.S. National Institutes of Health, Bethesda, MD).

Fig. 1. Mirabegron-induced UCP1 gene expression in mouse brown preadipocytes. Gene expression of brown fat cell differentiation markers: (A) UCP1, (B) PPARγ, (C) PRDM16, (D) CIDEA, (E) nuclear respiratory factor 1 (NRF1), and (F) DNA copies of cytochrome c oxidase subunit 2 (COXII). DMSO-treated cells were set as fold 1. All genes were normalized with 36B4. Data are presented as mean ± S.E.M. (n = 3). Bars without a common superscript differ, $P < 0.05$, and ns is not statistically significant.
Immunohistochemistry. The formalin-fixed tissue was embedded in paraffin and cut to 5-μm sections by the Department of Pathology of the Texas Tech University Health Sciences Center. Deparaffinized and rehydrated sections were incubated with anti-UCP1 antibody produced in rabbit (U6382, 1000× dilution; Sigma-Aldrich, St. Louis, MO) overnight at 4°C, followed by incubation with biotinylated secondary antibody for 1 hour. Then the sections were developed using avidin-conjugated horseradish peroxidase with diaminobenzidine as the substrate by using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA) in accordance with the manufacturer’s instructions. After development, the slides were mounted under coverslips with Permount, and images were taken under an Evos microscope (AMG) after 24 hours of drying. The UCP1 intensity was quantified via a reciprocal intensity method described previously elsewhere (Nguyen et al., 2013).

Quantitative Real-Time Polymerase Chain Reaction. Total RNA was extracted using TRIzol reagent (ThermoFisher Scientific, Waltham, MA) according to the manufacturer’s instructions. The total RNA abundance was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Complementary DNA was synthesized by using a Maximal First Strand cDNA Synthesis Kit for real-time quantitative polymerase chain reaction (PCR) with dsDNase (#K1671; Thermo Scientific, Pittsburgh, PA) according to the manufacturer’s instructions.

Quantitative real-time PCR was performed by using PowerUp SYBR Green Master Mix (Applied Biosystems, Austin, TX) in Hard-Shell 96-well skirted PCR plates (Bio-Rad Laboratories, Hercules, CA) and an Eppendorf Mastercycler ep realplex instrument. The PCR cycle conditions were 50°C for 2 minutes, 95°C for 2 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The relative gene expression was calculated by the comparative 2-ΔΔCt method using 36B4 as a reference gene. The sequences of forward and reverse primers are listed in Table 1.

Body Composition. The body composition analysis was performed at weeks 7 and 10 by using an EchoMRI Body Composition Analyzer (EchoMRI LLC, Houston, TX) according to the manufacturer’s instructions.

Glucose and Insulin Tolerance Tests. After 2 weeks of treatments, an intraperitoneal glucose tolerance test (IPGTT) was performed on awake mice fasted for 6 hours by intraperitoneal injection of glucose (2 g/kg body weight). After 3 weeks of treatments, an insulin tolerance test (ITT) was performed on awake mice fasted for 4 hours by intraperitoneal injection of Humulin-R-insulin (0.75 U/kg body weight) (Lilly USA, Indianapolis, IN). Blood glucose concentrations were measured from the tail vein by using a OneTouch Ultra2 glucometer (LifeScan Europe, Zug, Switzerland) at baseline and at 15, 30, 60, 90, and 120 minutes after injection.

Statistical Analysis. All data were analyzed by using Prism 7 (GraphPad Software, San Diego, CA) and are presented as mean ± S.E.M. One-way ANOVA with repeated measures followed by Newman-Keuls multiple comparisons test was performed to determine the differences among groups. P < 0.05 was considered statistically significant.

Results

Mirabegron Enhanced UCP1 Expression in Mouse Brown Preadipocytes. C57BL/6J mouse brown preadipocytes were treated with different concentrations of mirabegron (0.03, 0.3, and 3 μg/ml) during cell differentiation. Mirabegron enhanced UCP1 expression in a dose-dependent manner. As compared with the vehicle control (DMSO), mirabegron at the levels of 0.3 and 3 μg/ml significantly increased UCP1 expression (Fig. 1A). CL316243, a β3-agonist as a positive control, also increased UCP1 gene expression.

Neither mirabegron nor CL316243 significantly changed the expression of other brown adipocyte-related markers, such as PGC1α, PPARγ, CIDEA, TMEM26, and CD137. DMSO-treated cells were set as fold 1. All genes were normalized with 36B4. Data are presented as mean ± S.E.M. (n = 3). Bars without a common superscript differ, P < 0.05, and ns is not statistically significant.
as PPARγ, PR domain containing 16 (PRDM16), CIDEA, and nuclear respiratory factor 1 (NRF-1) (Fig. 1, B–E), or cytochrome c oxidase subunit 2 (COXII), a mitochondrial biogenesis marker (Fig. 1F). The mRNA levels of all tested brown adipocyte differentiation markers were significantly increased in cells treated with the vehicle control (DMSO) compared with the cells only exposed to growth medium, which demonstrated the successfullness of cell differentiation (Fig. 1, A–E).

**Mirabegron Increased Gene Expression of Browning-Related Markers in 3T3-L1 Adipocytes.** We further investigated the browning effect of mirabegron in differentiated 3T3-L1 white adipocytes in vitro. Mature 3T3-L1 adipocytes were treated with the vehicle DMSO, mirabegron (3 μg/ml), or isoproterenol (1 μM), a β3-agonist as a positive control for 6 hours. UCP1 gene expression was significantly elevated by 5.5-fold with mirabegron treatment compared with the vehicle control (DMSO) (Fig. 2A). PGC1α, one of the key regulators of browning, was also significantly up-regulated by mirabegron treatment compared with the vehicle control (DMSO) (Fig. 2B).

There were no differences in PPARγ and CIDEA expression between mirabegron and control (Fig. 2, C and D). Expression of transmembrane protein 26 (TMEM26) and CD137, two common markers for beige adipocytes, were also measured. TMEM26 expression was increased with mirabegron treatment compared with the vehicle control (Fig. 2E), but there were no differences in CD137 expression (Fig. 2F).

**Mirabegron Reduced Body Weight Gain in Mice Fed HFD.** Mice in the HFD + VEH group had significantly higher body weight and fat mass compared with those in the CHD group (Fig. 3, A and B). Mice in the HFD + MA group had 12% lower body weight and 25% lower fat mass than those in the HFD + VEH group (Fig. 3, A–C), although their food intake was not different. Compared with the mice treated with HFD + VEH, the mice treated with HFD + MA had significantly lower weight of iWAT, gonadal WAT (gWAT), and retroperitoneal WAT (rWAT) (Fig. 3D), while no significant difference was found in the iBAT mass (Fig. 3D). In addition, significantly improved glucose tolerance (Fig. 3E) and insulin sensitivity (Fig. 3F) were observed after 2 and 3 weeks of mirabegron treatment, respectively. Mirabegron had no effect on the plasma levels of cholesterol and triglyceride (data not shown).

**Mirabegron Reduced iBAT Whitening in Mice Fed HFD.** As compared with the CHD group, iBAT in the HFD + VEH group became filled with large lipid droplets, a phenotype called “whitening” and the lipid occupied surface area was significantly decreased in the HFD+MA group relative to the HFD + VEH group (Fig. 4, A and B). There were no differences in the mRNA expression of UCP1, PGC1α, PPARγ, and lipoprotein lipase (Fig. 4, C–F) in iBAT between HFD + VEH and HFD + MA groups. HFD + MA compared with HFD + VEH had an insignificant 2-fold increase in type II iodothyronine deiodinase (DIO2) gene expression in iBAT (Fig. 4G).

**Mirabegron Induced iWAT Browning in Mice Fed HFD.** H&E staining revealed that HFD + MA noticeably increased the abundance of multilocular adipocytes in iWAT, which is a hallmark of WAT browning (Fig. 5A). Immunohistochemistry showed that UCP1 protein in iWAT of mice treated with HFD + MA was more abundant compared with that in the HFD + VEH group (Fig. 5, B and C). Consistent

![Fig. 3. Mirabegron reduced body weight gain in mice fed a HFD. (A) Final body weight. (B) Fat mass. (C) Accumulated food intake per mouse. (D) Adipose tissue weight in different fat depots. (E) Glucose tolerance test (GTT). (F) Insulin tolerance test (ITT). Data are presented as mean ± S.E.M. (n = 6). *P < 0.05 compared with the HFD + VEH group. &P < 0.05 compared with the HFD + MA group. Bars without a common superscript differ, P < 0.05.
with the changes in iWAT morphology and UCP1 protein levels, iWAT UCP1 mRNA levels were also higher (13-fold) in the mice treated with HFD + MA (Fig. 5D). HFD + MA also increased the expression of CIDEA and carnitine palmitoyltransferase 1 (CPT1) compared with HFD + VEH (Fig. 5, E and F). In addition, the leptin mRNA expression in iWAT was slightly reduced by the HFD + MA treatment (Fig. 5G), which concurs with reduced iWAT mass. No difference was found in mRNA expression of elongation of very long chain fatty acids 3 (ELOVL3), PRDM16, medium-chain acyl-CoA dehydrogenase (MCAD), adipose triglyceride lipase (ATGL), and hormone-sensitive lipase (HSL) (Fig. 5, H–L).

Discussion

Increasing energy expenditure through stimulation of β3-AR in BAT might be an effective approach to treat obesity and metabolic syndrome (Ursino et al., 2009; Mund and Frishman, 2013). In the current study, we first investigated whether mirabegron could up-regulate brown fat activation-related markers in a mouse brown preadipocyte cell line and 3T3-L1 white preadipocytes. In mouse brown preadipocytes, we found that mirabegron significantly enhanced UCP1 gene expression at higher doses (0.3 and 3 μg/ml), which was comparable to CL316243, a well-known β3-AR agonist.

In 3T3-L1 white adipocytes, we observed that mirabegron up-regulated UCP1, PGC1α, and TMEM26, which are beige specific markers. β3-AR is known to activate the protein kinase A/p38/mitogen-activated protein kinase signaling pathway, which consequently increases UCP1 promoter activity and further induces UCP1 gene expression (Kissig et al., 2016). Collectively, our in vitro study demonstrated that mirabegron increased the transcripts for brown fat and beige related markers in mouse brown preadipocyte and white preadipocyte cell lines, which might further enhance the thermogenic activity of these cells.

In the animal study, we found that the delivery of mirabegron to iBAT reduced body weight gain and fat mass in mice fed HFD. Importantly, the mirabegron treatment ameliorated
BAT “whitening” caused by HFD feeding and enhanced beige adipocyte formation in iWAT. Obesity is associated with a dysfunction of BAT (Roberts-Toler et al., 2015). Specifically, HFD can lead to a BAT whitening phenotype that is characterized by mitochondrial dysfunction and large lipid droplet accumulation in brown adipocytes (Shimizu et al., 2014; Shimizu and Walsh, 2015). One recent study demonstrated that BAT whitening was attributed to the reduction of vascular endothelial growth factor a (VEGFa) signaling caused by HFD feeding (Shimizu et al., 2014). It would be interesting to investigate whether mirabegron regulates VEGFa signaling in a future study.

The iBAT UCP1 mRNA levels were similar among three groups, which is consistent with one study that reported that CL316243 improved BAT morphology but did not affect UCP1 gene expression (Xiao et al., 2015). In fact, one study revealed that even the strongest browning stimulus, cold, did not substantially increase UCP1 expression in iBAT when mice were housed at about 20°C, because BAT is already fully differentiated and the density of UCP1 reaches the highest capacity in brown adipocytes (Kalinovich et al., 2017).

In addition to the effects on iBAT, mirabegron stimulated browning of iWAT as indicated by the histology and gene expression data, which are consistent with other studies showing that chronic β3-AR agonist administration led to the presence of multilocular lipid droplets in WAT (Himms-Hagen et al., 2000) and enhanced the expression of UCP1 in WAT depots (Merlin et al., 2016). Similar to other β3-AR agonist–mediated transcriptional regulation, the binding of mirabegron to WAT β3-AR may elevate intracellular cAMP levels, which trigger intracellular signaling cascades such as activation of protein kinase A and phosphorylation of p38 mitogen-activated protein kinase, resulting in activation of transcription machinery and recruitment of transcription factors for UCP1 and other thermogenic genes (Merlin et al., 2016).

There are very limited data showing the effect of mirabegron on adipose tissue and other metabolic active tissues. One study showed that administering mirabegron (10 mg/kg per day) via gavage for 2 weeks decreased epididymal fat by 34% in obese C57BL/6 mice (Calmasini et al., 2017). Notably, a recent human study reported that mirabegron treatment (50 mg/day for 10 weeks) induced UCP1, TMEM26, and CIDEA expression in the subcutaneous WAT of obese subjects although their body weights were not significantly changed (Finlin et al., 2018), which supports the findings of our studies.

Interestingly, we found that mirabegron significantly improved glucose tolerance and insulin sensitivity. It is unclear at this point how mirabegron acts to favorably impact glucose homeostasis and insulin signaling, but we speculate that stimulation of fat oxidation by β3-AR agonists may quickly decrease intracellular fatty acyl CoA and diacylglycerol, which are known to inhibit insulin signaling (Arch, 2002). Indeed, our results suggest that mirabegron may enhance fatty acid oxidation by increasing the expression of CPT1 gene (Fig. 5F), one of the key enzymes regulating beta oxidation of long chain fatty acids.

In addition, mounting evidence suggests that BAT functions as a glucose clearing organ (Festuccia et al., 2011; Lee et al., 2016). Therefore, the antidiabetic effects of mirabegron may be partially attributed to the release of brown adipokines by BAT, such as insulin-like growth factor I, C-X-C motif chemokine ligand-14, and fibroblast growth factor-21 (Townsend and Tseng, 2012; Villarroya et al., 2013; Cereijo et al., 2018). Furthermore, the reduction of adiposity per se may improve glucose tolerance and insulin sensitivity. Finally, similar to...
mirabegron, chronic administration of other β3-AR agonists has been shown to improve glucose homeostasis as well (Kim et al., 2006; Fu et al., 2008). Further studies are warranted to investigate these mechanisms.

Our study has several limitations. First, calorimetry was not performed in the animal study, so we cannot directly verify that mirabegron increased energy expenditure in these obese mice. In addition, the cardiovascular effects of mirabegron were not tested in our in vivo models. As any β3-AR agonist may have an off-target cardiovascular effect (Andersson, 2017), the safety of mirabegron on the cardiovascular system should be carefully examined. Notably, one study has found that mirabegron did not increase cardiovascular risk at a dose of 100 mg in healthy subjects, but higher doses (150 and 200 mg) increased blood pressure (Loh et al., 2019). Finally, the mice were only placed in 22°C, not in thermoneutrality. As housing temperature has marked effects on rodent physiology, it should be carefully examined. Notably, one study has found that mice housed at 22°C had decreased body fat compared to mice housed at 30°C (Harms et al., 2011). Our study has several limitations. First, calorimetry was not performed in the animal study, so we cannot directly verify that mirabegron increased energy expenditure in these obese mice. In addition, the cardiovascular effects of mirabegron were not tested in our in vivo models. As any β3-AR agonist may have an off-target cardiovascular effect (Andersson, 2017), the safety of mirabegron on the cardiovascular system should be carefully examined. Notably, one study has found that mirabegron did not increase cardiovascular risk at a dose of 100 mg in healthy subjects, but higher doses (150 and 200 mg) increased blood pressure (Loh et al., 2019). Finally, the mice were only placed in 22°C, not in thermoneutrality. As housing temperature has marked effects on rodent physiology, it should be carefully examined. Notably, one study has found that mice housed at 22°C had decreased body fat compared to mice housed at 30°C (Harms et al., 2011).

In summary, the results of our current studies indicate that mirabegron can enhance UCP1 expression in mouse adipocytes and white adipocytes and promote browning of iWAT, which are associated with beneficial effects in protecting against HFD-induced obesity and improving glucose tolerance and insulin sensitivity. Our findings further support further investigation of whether mirabegron could stimulate the recruitment of beige cells and improve glucose homeostasis in human subjects.

Acknowledgments

The authors thank Dr. Jie Liu (Texas Tech University) for her help in the animal study.

Authorship Contributions


References


Arch JR (2011) Challenges in investigating whether mirabegron could stimulate the recruitment of beige cells and improve glucose homeostasis in human subjects.


Beneficial Metabolic Effects of Mirabegron


Address correspondence to: Dr. Shu Wang, Department of Nutritional Sciences, Texas Tech University, Box 41270, Lubbock, TX 79409-1270. E-mail: shu.wang@ttu.edu; or Dr. Lei Hao, Department of Nutritional Sciences, Texas Tech University, Box 41270, Lubbock, TX 79409-1270. E-mail: lei.hao@ttu.edu